Clinical trial
The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's…
NCT00163085 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00163085 |
|---|---|
| Title | The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Explore The Efficacy And Safety Of The NR2B NMDA Antagonist CP-101,606 In Patients With Idiopathic Parkinson's Disease |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug |
| Interventions | NR2B NMDA Antagonist CP-101, 606 (traxoprodil) |
| Enrollment | 12 |
| Start date | May 1, 2005 |
| Completion | Jan 1, 2006 |
| First posted | Sep 13, 2005 |
| Last update posted | Sep 22, 2006 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: